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Cisplatin (CDDP) has been a key drug for chemotherapy in
patients with head and neck squamous cell carcinoma. Nephro-
toxicity is one of its adverse reactions that are dose limiting. To
increase its antitumor effects and reduce such toxicity problems,
polymeric micelles carrying CDDP (NC-6004) have been devel-
oped. The present study was designed to evaluate the efficacy
and safety of NC-6004 for oral squamous cell carcinoma. In vitro
antitumor activity was assayed in four oral squamous cell carci-
noma cell lines. To investigate the antitumor and nephrotoxic
effects of NC-6004, nude mice bearing OSC-19 were administered
NC-6004 or CDDP. The in vitro growth-inhibitory effect of NC-6004
was significantly less than that of CDDP. However, both NC-6004
and CDDP showed equivalent antitumor effects in vivo. Mice
with CDDP developed renal cell apoptosis; however, those
injected with NC-6004 were almost free of renal cell injury. More-
over, in an orthotopic tongue cancer model using OSC-19,
NC-6004 reduced the rate of sentinel lymph node metastasis to
lower than that with CDDP. In conclusion, considering the poten-
tial advantages in terms of noticeable antitumor activity, lympha-
tic drug delivery and reduced nephrotoxicity, NC-6004 represents
a significant structural improvement in the development of a
platinum complex. (Cancer Sci 2013; 104: 369–374)
H ead and neck cancer remains a significant public healthproblem and ranks in the six leading cancers by inci-
dence worldwide, with an estimated 600 000 new cases every
year.(1) Cisplatin (cis-dichlorodiammineplatinum; CDDP) has
been demonstrated to be one of the most effective cytotoxic
agents (2) and the CDDP-based chemotherapy regimen has
gained widespread use in patients with head and neck squa-
mous cell carcinoma (HNSCC). However, its administration
has been hindered by its adverse reactions, for example, neph-
rotoxicity, neurotoxicity, gastrointestinal toxicity, hematologi-
cal toxicity and ototoxicity.(3) Among these, the significant risk
of nephrotoxicity frequently hinders the use of high doses to
maximize its antineoplastic effects, which might be the cause
of treatment failure.
To overcome these problems and improve the therapeutic
effect of CDDP, we have been applying superselective supra-
dose intra-arterial CDDP infusion for advanced HNSCC.(4)
However, since this technique is more complicated than that of
i.v. infusion of antitumor drugs, it is not prevalent in the che-
motherapy scene. Recently, several kinds of nanoparticle thera-
peutic platforms, including liposomes, nanoparticles and
polymeric micelles, have been developed based on the idea
that the drug delivery system (DDS) can accumulate in the
tumor selectively, with reduced distribution in normal tissues
and minimized undesirable side-effects.(5–7) NC-6004, which is
a CDDP-incorporating polymeric micellar nanoparticle,
enhanced antitumor activity and reduced the nephrotoxicity
and neurotoxicity of CDDP in gastric cancer.(8–10) Poly(ethyl-
ene glycol)-poly(glutamic acid) block copolymers (PEG-P
[Gu]) confer a stealth property to the formulation, which
allows the micellar drug preparation to be less avidly taken up
by the reticuloendothelial system and retained in the circula-
tion for a longer period of time. This has been recognized as
the enhanced permeability and retention (EPR) effect where
extravasation of high-molecular-weight micelles through leaky
tumor capillary fenestrations, which result from abnormalities
in angiogenesis at the tumor site, lead to accumulation and
retention for a long time.(11) A prolonged circulation time and
the ability of EPR lead to the accumulation of CDDP in tumor
tissues. NC-6004 has been previously shown to possess signifi-
cant antitumor activity for human gastric cancer cells in a
mouse model.(10) However, the efficacy of NC-6004 in head
and neck cancer has never been studied.
In the present study, we analyzed the cytotoxicity of NC-6004
using the MTS assay and apoptosis assay on oral squamous
cell carcinoma cell lines. Antitumor and nephrotoxic effects of
NC-6004 were investigated and compared with those of CDDP
in in vivo experiments. As frequent involvement of regional
lymph nodes, especially the sentinel lymph node (SLN), is one
of the outstanding features of oral SCC, we further evaluated
the lymphatic distribution of NC-6004 in order to develop a
target therapy for cervical lymph node metastasis, which also
has never been evaluated.
Materials and Methods
Materials. Human oral squamous cell carcinoma cell lines
OSC-19, OSC-20, HSC-3 and HSC-4 were used for these
experiments. OSC-19 and OSC-20 were maintained in Eagle’s
minimum essential medium supplemented with 10% fetal
bovine serum. HSC-3 and HSC-4 were maintained in Dul-
becco’s modified Eagle’s medium with 10% fetal bovine
serum. Luciferase-transfected OSC-19 LN2-Luc cells were
kindly provided by Dr Jeffrey N. Myers (The University of
Texas MD Anderson Cancer Center, Houston, TX, USA).(12)
The CDDP was obtained from Nippon Kayaku Co., LTD
(Tokyo, Japan). NC-6004 was supplied by NanoCarrier Co.
Ltd (Chiba, Japan).(9) The luciferase antibody was purchased
from MBL (Nagoya, Japan). 6-week-old female BALB ⁄ c-nu
⁄nu mice were purchased from Charles River Japan Inc.
(Kanagawa, Japan). All animal procedures were performed in
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compliance with the guidelines for the Ethical Committee of
the Laboratory for Animal Experiments, Graduate School of
Medical Science, Kanazawa University.
In vitro growth-inhibition assay. Head and neck cancer cell lines
were evaluated in the present study. A 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt
(MTS) assay was performed to assess the effect of cell prolif-
eration using the CellTiter 96 Aqueous One Solution Cell
Proliferation Assay (Promega, WI, USA). Briefly, cells were
seeded in 96-well culture plates at a density of 2 9 103 cells ⁄
well. After 24 h incubation with 0.9% NaCl (control), a graded
concentration of CDDP or NC-6004 was added to each well
and incubated for 48 or 72 h. Following 2 h incubation of
MTS reagent, optical density was read with a Microplate
Reader Manager (Molecular Device, Sunnyvale, CA, USA) at
a wavelength of 490 nm. The IC50 values represented the drug
concentrations that reduced the mean absorbance at 490 nm to
50% in the untreated control well.
Apoptosis assay. Before incubation with drugs, OSC-19 cells
were cultured in serum-free medium for 24 h. Then, with a
series of CDDP- or NC-6004-containing medium for 24 h, cas-
pase-3 activity was measured using the Caspase-Glo 3 ⁄7 Assay
(Promega, WI, USA) according to the manufacturer’s instruc-
tions. Briefly, cells with CDDP or NC-6004 were added with
Caspase-Glo 3 ⁄7 Reagent (promega) to each well of the 96-
well plate. The luminescence of each sample was measured
with a Typhoon9200 imager (GE Healthcare UK Ltd, Amer-
sham, UK).
Evaluation of antitumor activity. For this experiment,
1 9 105 OSC-19 cells were injected s.c. on the dorsal skin of
BALB ⁄ c-nu ⁄nu mice. When tumor diameters reached 3 mm,
tumor-bearing mice were allocated randomly to drug adminis-
tration groups. There were three test groups as follows: control
group; CDDP treatment; and NC-6004 treatment. Drugs were
injected i.v. via the tail vein each week, with three administra-
tions in total. Mice were administered a single i.v. injection of
5% glucose solution (control), CDDP (5 mg ⁄kg) or NC-6004
(an equivalent dose of 5 mg ⁄kg CDDP). The tumor volume
was calculated using the formula: tumor volume
(mm3) = a 9 b (where a is the longest tumor diameter and b
is the shortest tumor diameter).
TUNEL assay. A TUNEL assay was performed for the detec-
tion and quantitation of kidney cell apoptosis, as previously
described.(13) The ApoAlert DNA Fragmentation Assay Kit
obtained from Clontech (La Jolla, CA, USA) was used to
assess apoptosis-induced nuclear DNA fragmentation via a
fluorescence assay. On day 28 after administration of the
drug, the mice, in which the same experimental protocol
described in “Evaluation of antitumor activity” was used,
were killed. The kidney was removed and serum was
collected. The kidney was fixed in 10% formalin solution.
Paraffin sections were deparaffinized. TUNEL-positive apop-
totic cells were detected using visualization with a fluorescent
microscope. The number of apoptotic cells per 100 at five
fields in the tubule cells of the kidney was counted. In each
blood sample, the plasma concentrations of creatinine were
measured by SRL Laboratories (Tokyo, Japan).
Assessment of cervical lymph node metastasis. BALB ⁄ c-nu ⁄nu
mice were anesthetized and 1 9 105 OSC-19 LN2-Luc cells
were then injected submucosally into the right side of the
tongue using a tuberculin syringe with a 30-gauge hypoder-
mic needle.(14) Mice were administered a sublingual injection
of 5% glucose solution (control), CDDP (5 mg ⁄kg) or NC-
6004 (an equivalent dose of 5 mg ⁄kg CDDP) each week
around the implanted tumor, with three administrations in
total. On day 21 after implantation of OSC-19 LN2-Luc
cells, the mice were killed. Cervical lymph nodes were
resected and histopathologically examined using HE staining
and luciferase staining to confirm the presence or absence of
tumors. The presence of lymphatic metastasis was compared
among groups.
For the pharmacokinetic study, drug concentrations were
measured in cervical lymph nodes and plasma. After the injec-
tion of CDDP or NC-6004, samples were collected at 1, 24, 72
and 144 h.
Statistical analysis. Data were expressed as the mean  SD.
Differences between test groups were analyzed using the Stu-
dent’s t-test. The SPSS statistical software version 18 (SPSS
Japan Inc., Tokyo, Japan) was used. A value of P < 0.05 was
considered to be significant.
Results
Sensitivity of oral cancer cells to CDDP. The cytotoxicity of
NC-6004 was evaluated in comparison to that of CDDP in oral
carcinoma cell lines. The IC50 values, calculated from dose-
survival curves obtained after 48 and 72 h treatment from the
MTS assay, were investigated (Table 1). The IC50 values for
CDDP ranged from 16.5 to 28.3 lM at 48 h and 17.6 to
20.5 lM at 72 h. NC-6004 showed a growth inhibitory
potency that was lower than that of CDDP, with IC50 values
ranging from 118.9 to 398.4 lM at 48 h and 113.9 to
119.3 lM at 72 h. The growth inhibitory effect of CDDP in
vitro was seven- to 14-fold more potent than that of NC-6004.
Upregulation of caspases by cisplatin and NC-6004. When
OSC-19 cells were exposed to increasing concentrations of
CDDP, caspase-3 and caspase-7 were activated in a dose-
dependent manner. Neither CDDP nor NC-6004 significantly
influenced caspase activity at a concentration of 0.05 lg ⁄lL.
However, CDDP and NC-6004 increased caspase activity at a
concentration of 2.5 lg ⁄lL by approximately 142–331% and
165–170%, respectively (Fig. 1). These data indicate that both
drugs induced apoptosis in a dose-dependent manner, which
relied on caspase-3 and caspase-7 activation.
Antitumor activity of NC-6004 on OSC-19 xenograft. The anti-
tumor activity of NC-6004 or CDDP was evaluated in oral car-
cinoma-bearing mice. All mice survived the experiment. In
OSC-19 xenografts, the tumor started to grow on day 14. On
day 35, mice treated with either CDDP or NC-6004 showed
4.9- or 6.6-fold tumor growth inhibition relative to the control
group, respectively (Fig. 2). There were no significant differ-
ences for the growth inhibitory effect between the two groups
receiving chemotherapy.
Decreased nephrotoxicity of NC-6004 to CDDP in mice. Nude
mice given an injection of CDDP or NC-6004 at a dose of
10 mg ⁄kg were used to evaluate the structural and functional
consequences of CDDP-induced nephrotoxicity. In the control
group, no apoptosis in the tubule cells of the kidney was
detected. Drug-induced tubule cell apoptosis was recognized as
TUNEL-stained cells (Fig. 3a–c). Apoptotic cells from CDDP-
or NC-6004-treated mice were counted and scored as structural
Table 1. The 50% inhibitory concentration (IC50) values of cisplatin
(CDDP) and NC-6004 (lM)
Cell line
IC50
48 h 72 h
CDDP NC-6004 CDDP NC-6004
OSC-19 28.3 129.3 17.6 117.0
OSC-20 22.4 398.4 18.4 113.9
HSC-3 11.2 110.5 10.2 71.7
HSC-4 16.5 118.9 20.5 119.3
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damage. The number of apoptotic cells in NC-6004-treated
mice was significantly lower than that in CDDP-treated mice
(P = 0.0085), and was similar to that in control mice (Fig. 3d).
To examine functional damage, serum creatinine levels were
measured. While the CDDP-treated mice showed significantly
higher serum creatinine than the control group, NC-6004-treated
mice showed comparable levels of serum creatinine to the
control (Fig. 3e). These results indicate that NC-6004 is less
toxic to the kidney than CDDP.
Efficacy of translymphatic chemotherapy and CDDP distribution
in lymph nodes. To detect metastatic lymph nodes, an ortho-
topic xenograft mouse model of luciferase-transfected OSC-19
LN2-Luc cells was made. Primary tongue tumors were
detected at the cell-inoculated site in all mice. Cervical lymph
nodes were easily identified in OSC-19-inoculated mice and
control mice as previously reported (Fig. 4a).(14) As it was not
possible to distinguish the nodes with metastasis from the ones
without metastasis macroscopically, HE and luciferase staining
was performed to reveal the presence of metastases microscop-
ically (Fig. 4b). The incidence of lymphatic metastasis was
significantly lower in the NC-6004-treated group (one of eight)
than that of the controls (seven of eight) and the CDDP-treated
group (three of eight; P < 0.01; Fig. 4c). The time-course of
elemental platinum (Pt) concentrations in plasma and cervical
lymph nodes after sublingual injection of CDDP or NC-6004
was measured (Fig. 4d). Both plasma and lymph node concen-
trations after administration of NC-6004 peaked at 24 h, repre-
senting remarkably prolonged blood and lymphatic circulation;
however, Pt was cleared rapidly from circulation in the CDDP
group. AUC0–144 h for plasma and lymph nodes in the NC-6004
group were significantly higher than those in the CDDP group.
Although at day 6 (144 h) the Pt levels in plasma were unde-
tectable in both groups, lymph nodes of the NC-6004 group
still showed a high Pt concentration (1.15  0.34 lg ⁄g).
Discussion
Cancer nanotechnology is a new field of interdisciplinary
research aiming to enhance the methods of cancer diagnosis
and treatment.(15) From the standpoint of DDS targeting solid
carcinoma, a variety of polymeric micelle-based anticancer
drugs have been developed to achieve high and selective accu-
mulation at the tumor site.(16–18) CDDP is a key drug in che-
motherapy for malignancies such as lung, gastrointestinal,
genitourinary and head and neck cancer.(2) Studies have shown
that NC-6004 caused better selective accumulation of CDDP
in tumors while lessening its distribution in normal tissue.(9)




Fig. 2. Effect of cisplatin (CDDP) or NC-6004 in
OSC-19 mouse models. The OSC-19 cell line was
inoculated into the dorsal skin of nude mice.
Photographs of representative mice and tumors
treated with drugs are shown (A–C). (D) Reduced
tumor volume treated with CDDP and NC-6004
relative to the control group. Each data point is the
mean value (SD) of six primary tumors.
Fig. 1. Caspase-3 and caspase-7 activity in OSC-19 cells after 24 h
exposure to cisplatin (CDDP) () or NC-6004 (). Caspase activity was
measured using a fluorimetric assay. Values represent means  SD
from three independent experiments.
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hydrophilic poly(ethylene glycol) shell layer, is not detected
by macrophages, can be retained in the circulation for long
periods, is redistributed in tissue and can extravagate preferen-
tially to infiltrate solid tumors. In the present study, we have
investigated the antitumor properties and nephrotoxic effects
of NC-6004 on human oral cancer cell lines. Moreover, a sub-
mucosal injection of NC-6004 exhibited substantial therapeutic
efficacy in inhibiting cervical lymphatic metastasis in an ortho-
topic tongue cancer model.
To characterize the cellular basis of NC-6004 cytotoxicity
relative to CDDP, we tested the two drugs in four different
oral squamous carcinoma cell lines. The success of CDDP lies
in its ability to arrest DNA synthesis, induce oxidative stress
and activate apoptotic pathways in tumor cells.(19) The growth-
inhibitory effect of NC-6004 was significantly less than that of
CDDP. The different effects between these two drugs lies in
the slow release of CDDP in the presence of abundant chloride
ions as NC-6004 contains coordination bonds between the
atoms of Pt in CDDP and the carboxylic group in the side
chain,(10) which is in line with previous studies.(9,10) The cas-
pase cascade is activated when a CDDP stimulus induces the
release of cytochrome c from mitochondria.(20) This activation
leads to an irreversible commitment to apoptotic cell death.
We found that activation of caspase-3 and caspase-7 was
induced in both CDDP- and NC-6004-treated OSC-19 cells.
Nephrotoxicity is one of the most significant adverse effects
of CDDP.(21) CDDP accumulates in cells from all nephron
segments, but is preferentially taken up by the highly susceptible
proximal tubular epithelial cells, which bear the brunt of the
damage. This nephrotoxicity limits the dose that can be adminis-
tered and prevents the potential efficacy of CDDP.(22) The size
of NC-6004 is approximately 30 nm in diameter, which is large
enough to avoid renal secretion.(9) The Cmax value for Pt concen-
trations in the kidney after NC-6004 administration is much
lower than that of free CDDP administration.(9) In the present
study, the number of apoptotic renal cells in NC-6004-treated
mice was significantly lower than that in CDDP-treated mice by
approximately 66% (CDDP, 14.2%; NC-6004, 4.2%). Reduc-
tions in nephrotoxicity of NC-6004 might allow patients to
undergo therapy without hospitalization for hydration and the
treatment of CDDP-related toxicities.(23)
We evaluated the in vivo antitumor activity of NC-6004 in
mice. Reductions in tumor size after administration of NC-6004
or CDDP were approximately 14–20%, respectively, and were
not significantly different from each other. The data obtained
could be interpreted as these micelles having efficacy against
oral squamous cell carcinoma cell lines similar to that of
CDDP, but with much less renal toxicity toward the host.
The presence of cervical lymph node metastasis is an indica-
tor of poor prognosis in patients with HNSCC.(24–27) Recently,
the SLN has been highlighted as the lymph node that first
receives lymphatic drainage from the primary site of a
tumor.(28) To control lymph node metastasis, especially SLN
micrometastasis in the early stages, drugs need to be delivered
in tumoricidal concentrations from the site of application. The
drug is highly selective depending on the size of molecule to
access the lymphatic system, which was reported as the “blood–
lymph barrier”. The blood–lymph barrier makes conventional
anticancer agents fail to effectively enter the lymphatic sys-
tem.(29) The present study showed that sublingual injection of
NC-6004 in an orthotopic tongue cancer mouse model signifi-
cantly reduced lymphatic tumor metastasis. Moreover, a high
concentration of Pt in cervical lymph nodes was maintained
for at least 24 h after administration of NC-6004, whereas
CDDP was not delivered to lymph nodes, which is attributable
to the lymphatic drug delivery of NC-6004 from the primary
tumor. These results suggest that this new drug-delivery sys-
tem and the accumulation of micelles in lymph nodes are
feasible for local chemotherapy targeting SLN in patients with




Fig. 3. Low renal toxicity of NC-6004. Mice were
treated with cisplatin (CDDP) (10 mg ⁄ kg) or NC-6004
(an equivalent dose of 10 mg ⁄ kg CDDP) and kidney
sections were obtained on day 28 after administration
of the drug. (A–C) Immunofluorescence staining of
clusters of TUNEL-positive nuclei (green) and DAPI
(red). (D) The number of apoptotic cells per 100
were counted. Bars indicate standard deviations.
*P = 0.0085 for CDDP versus NC-6004. Each group
included five mice. (E) Plasma concentration of
creatinine (mg ⁄dL) after treatment with the control,
CDDP or NC-6004. *P = 0.0021 for CDDP versus
NC-6004. Each group included five mice.
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We did not examine Pt concentrations in cervical lymph
nodes with intravenous infusion of NC-6004 and CDDP.
However, Pt concentrations in the SNL were higher in the
NC-6004-injected group than CDDP in topically infused
groups, indicating that NC-6004 is more suitable for a lympha-
tic delivery system. These results suggest that such polymeric
micelled-drugs, which accumulate in higher concentrations
around the primary tumor than NC-6004, might be more suit-
able for the control of lymphatic disease in HNSCC.
The present study demonstrated the superior safety and anti-
tumor efficacy of NC-6004 against head and neck cancer cells
over that of CDDP. Considering the potential advantages in
terms of noticeable antitumor activity, lymphatic drug delivery
and reduced nephrotoxicity, NC-6004 represents a significant
structural improvement in the development of a platinum com-
plex. NC-6004 has progressed to a phase I clinical trial in the
UK,(23) and phase I ⁄ II trials are currently underway in East
Asia.
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Fig. 4. Translymphatic chemotherapy targeting
lymph nodes. (A) Tongue tumor and cervical lymph
node metastasis of an orthotopic xenograft model.
OSC-19 LN2-Luc cells were inoculated to the right
side of the tongue of nude mice. Mice were killed
after 35 days. A primary tumor (left, arrowhead)
and cervical lymph node (right, arrowhead) were
seen in the tongue. (B) Photomicrograph of lymph
node metastasis. HE stain (right) and luciferase stain
(left). (C) The rate of lymphatic metastasis. Each
group included eight mice. (D) Time-course of
elemental platinum (Pt) concentrations in plasma
and cervical lymph nodes (LN) after sublingual
injection of cisplatin (CDDP) (5 mg ⁄ kg) or NC-6004
(an equivalent dose of 5 mg ⁄ kg CDDP).
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